

CONSOLIDATED INCOME STATEMENT

For the year ended 31 December 2005

	Notes	2005 HK\$'000	2004 HK\$'000
Turnover	6	85,478	64,179
Cost of sales		(59,568)	(12,575)
Gross profit		25,910	51,604
Other operating income	7	4,714	3,383
Marketing, selling and distribution costs		(19,981)	(24,039)
Administrative expenses		(29,159)	(43,355)
Research and development expenditure		(1,706)	(1,500)
Loss on disposal of beneficial rights to a drug under development		-	(400)
Loss on disposal of investments in securities	8	-	(41,293)
Impairment loss for doubtful debts	9	(2,873)	(2,391)
Loss from operations	10	(23,095)	(57,991)
Finance costs	12	(108)	(289)
Loss before taxation		(23,203)	(58,280)
Taxation	13	(1,197)	(2,504)
Loss for the year		(24,400)	(60,784)
Attributable to:			
Equity holders of the Company		(24,095)	(60,992)
Minority interests		(305)	208
		(24,400)	(60,784)
Loss per share (HK cents)	16		
- Basic		(0.90)	(2.38)
- Diluted		N/A	N/A